News Archive

  • 12.23.2022  |  Lumen Bioscience awarded $3.6 million by U.S. Army to advance low-cost, scalable preventative for antibiotic-resistant infections

    Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced the receipt of a $3.6 million award from the Department of Defense (DoD)

    Full Story

  • 12.05.2022  |  SpeeDx co-founders win prestigious Prime Ministers Prize for Innovation

    Adjunct Professor Alison Todd and Dr Elisa Mokany have received the Prime Minister’s Prize for Innovation in the 2022 Prime Minister’s Prizes for Science.

    Full Story

  • 05.23.2022  |  GenomeKey raises Innovate UK funding to drive life-saving next-gen sepsis diagnostic

    The funding will enable the Bristol-based research and development company to provide rapid bacterial species identification and antimicrobial profiling in the hospital, which will save lives, money and antibiotics for the future

    Full Story

  • 04.12.2022  |  bioMérieux strengthens its commitment to fight antimicrobial resistance with the acquisition of Specific Diagnostics, an innovative company focusing on fast AST solution

    bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has entered into an agreement to acquire Specific Diagnostics, a privately held U.S. based company that has developed a rapid antimicrobial susceptibility test (AST) system

    Full Story

  • 03.10.2022  |  Pattern Bioscience appoints Carey-Ann Burnham as Chief Clinical Officer

    Renowned microbiologist will bring clinical expertise as the company advances its platform for rapid pathogen identification and antibiotic susceptibility testing

    Full Story

  • 02.08.2022  |  Bugworks Research bags $18 million in funding round led by Lightrock India, others

    Bugworks Research said it will continue to invest in its proprietary drug discovery platforms GYROX (for AMR) and DARE (for Immuno-oncology or IO), and identify new drugs for serious, underserved indications.

    Full Story